CSIMarket
 
Interpace Biosciences Inc   (PDII)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) 34
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 1

Interpace Biosciences Inc
Interpace Biosciences Inc is a biotechnology company that focuses on developing and commercializing molecular diagnostics tests and related products for diagnosing and treating various types of cancer. The company's tests are based on analyzing genetic and other molecular markers within a patient's tumor tissue or blood sample, providing physicians with information that can help guide personalized treatment decisions. Interpace Biosciences Inc aims to provide accurate and reliable diagnostic solutions that improve patient outcomes and contribute to the advancement of precision medicine.


   Company Address: Waterview Plaza Parsippany 7054 NJ
   Company Phone Number: 776-6419   Stock Exchange / Ticker: PDII
   PDII is expected to report next financial results on March 26, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Interpace Biosciences Inc

Interpace Biosciences Inc Achieves Remarkable Profitability and Revenue Growth, Paving the Way for a Promising Future



Interpace Biosciences Inc, a Medical Equipment & Supplies company, recently released its financial results for the most recent fiscal period. The comprehensive analysis of these results presents remarkable improvements in both profitability and revenue. In this article, we will explore how these financial achievements may influence the company's future prospects.
1. Profitability:
During the latest fiscal period, Interpace Biosciences Inc achieved a significant turnaround in profitability. The company reported a positive profit of $0.04 per share, compared to a loss of $-0.93 per share in the same period the previous year. However, it is worth noting that profits declined by 50% from the preceding reporting period, where earnings were $0.08 per share. This decrease should be monitored closely to assess its impact on the company's financial health.

Interpace Biosciences Inc

Interpace Biosciences Inc. Surprises Investors with Striking Earnings Rebound, but Will it Last against Declining Revenue?

Interpace Biosciences Inc.: A Surprising Turnaround, But Is It Built to Last?
Interpace Biosciences Inc. surprised investors by posting earnings per share (EPS) of $0.08 for the financial interval that ended on March 31, 2023, compared to a loss of $0.53 per share a year earlier. The company also reported that its income per share had turned positive, a marked improvement from the prior reporting period. While this news may have caught many off guard, a closer look at the financials reveals some reasons for skepticism about the company's ability to sustain this momentum going forward.
Revenue Decline Raises Red Flags
One cause for concern is Interpace Biosciences' decline in revenue. The company reported revenue of $9.83 million for the financial interval ending March 31, 2023, a decrease of 5.31% from the $10.38 million generated in the comparable reporting period a year before. While the sequential revenue gain of 150.599% from $3.92 million is a notable improvement, it is difficult to discern whether this reflects true growth in the business or merely a return to pre-pandemic levels.






 

Interpace Biosciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com